| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
BridgeBio Pharma, Inc.
13D/A
Amendment 7
BBIO · 10806X102
|
4.7% |
8/17/2026
Event 8/13/2026
|
|||
| KKR Genetic Disorder L.P. | 4.2% | ||||
| KKR Genetic Disorder GP LLC | 4.2% | ||||
| KKR Group Partnership L.P. | 4.7% | ||||
| KKR Group Holdings Corp. | 4.7% | ||||
| KKR Group Co. Inc. | 4.7% | ||||
| KKR & Co. Inc. | 4.7% | ||||
| KKR Management LLP | 4.7% | ||||
| Henry R. Kravis | 4.7% | ||||
| George R. Roberts | 4.7% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 6
BBIO · 10806X102
|
7.0% |
5/14/2025
Event 5/12/2025
|
|||
| KKR Genetic Disorder L.P. | 7.0% | ||||
| KKR Genetic Disorder GP LLC | 7.0% | ||||
| KKR Group Partnership L.P. | 7.0% | ||||
| KKR Group Holdings Corp. | 7.0% | ||||
| KKR Group Co. Inc. | 7.0% | ||||
| KKR & Co. Inc. | 7.0% | ||||
| KKR Management LLP | 7.0% | ||||
| Henry R. Kravis | 7.0% | ||||
| George R. Roberts | 7.0% | ||||
|
BridgeBio Pharma, Inc.
13D/A
Amendment 5
BBIO · 10806X102
|
10.1% |
3/7/2025
Event 3/5/2025
|
|||
| KKR Genetic Disorder L.P. | 10.1% | ||||
| KKR Genetic Disorder GP LLC | 10.1% | ||||
| KKR Group Partnership L.P. | 10.1% | ||||
| KKR Group Holdings Corp. | 10.1% | ||||
| KKR Group Co. Inc. | 10.1% | ||||
| KKR & Co. Inc. | 10.1% | ||||
| KKR Management LLP | 10.1% | ||||
| Henry R. Kravis | 10.1% | ||||
| George R. Roberts | 10.1% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.